RBC Capital Raises Price Target for Verastem (NASDAQ: VSTM) Amid Promising Clinical Trial Data

• RBC Capital has significantly increased its price target for Verastem to $15.00, reflecting strong confidence in the biopharmaceutical company's outlook.
• The biopharmaceutical company reported encouraging preliminary data from its TARGET-D 101 Phase 1/2 clinical trial for VS-7375, a drug targeting KRAS G12D-mutated solid tumors.
• Further positive results from the RAMP 205 clinical trial highlight Verastem's progress in addressing first-line metastatic pancreatic cancer, a disease with high unmet medical need.

On June 24, 2026, an analyst from RBC Capital set a new price target for Verastem (NASDAQ: VSTM) at $15.00, a significant increase from its trading price of $4.33 at the time. Verastem is a biopharmaceutical company that focuses on developing new medicines to treat cancer by targeting specific genetic mutations.

This optimistic price target follows positive news from the company's drug pipeline. As highlighted by Business Wire, Verastem announced encouraging preliminary data from its TARGET-D 101 Phase 1/2 clinical trial. The trial is studying VS-7375, an oral drug designed to inhibit KRAS G12D-mutated solid tumors.

The early data shows that VS-7375 has promising clinical activity and a good safety profile. The drug is being tested in patients with several types of advanced cancers, including pancreatic, colorectal, and non-small cell lung cancer. Positive results in clinical trials are a key step for a biopharmaceutical company.

Verastem also reported positive updated results from its RAMP 205 clinical trial. This study is testing a combination of two drugs, avutometinib and defactinib, with standard chemotherapy. The goal is to treat patients with first-line metastatic pancreatic cancer, a disease with a high unmet medical need.

The company explains that the KRAS gene is mutated in over ninety percent of pancreatic cancers, making it a key target for treatment. With a market capitalization of around $296.00 million, Verastem's progress in these clinical trials is a critical factor for investors watching the stock.